FDA and FTC warned LeRoche Benicoeur dba ConceiveEasy that its ConceiveEasy fertility product was sold as an unapproved new drug with unsupported disease claims.
What happened
FDA reviewed www.conceiveeasy.com in March 2021 and found the firm takes orders there for ConceiveEasy. FDA said website and social media claims show the product is intended to cure, mitigate, treat, or prevent disease, making it a new drug without FDA approval and misbranded for lacking adequate directions. FTC reviewed the website in May 2021 and said it was concerned efficacy claims may not be supported by competent and reliable scientific evidence.
What FDA found
Website claims show ConceiveEasy is intended to cure, mitigate, treat, or prevent disease, so it is a drug.
FD&C Act §201(g)(1)(B) [21 U.S.C. §321(g)(1)(B)]ConceiveEasy is a new drug because it is not generally recognized as safe and effective for its claimed uses and has no FDA approval.
FD&C Act §§201(p), 301(d), 505(a) [21 U.S.C. §§321(p), 331(d), 355(a)]The product is misbranded because it lacks adequate directions for use, and its intended diseases cannot be safely self-diagnosed or self-treated without a licensed practitioner.
FD&C Act §502(f)(1) [21 U.S.C. §352(f)(1)]; 21 C.F.R. §201.5Introducing the misbranded drug into interstate commerce violates the Act.
FD&C Act §301(a) [21 U.S.C. §331(a)]FTC said advertising that a product can prevent, treat, or cure human disease requires competent and reliable scientific evidence, and it was concerned these claims may not be substantiated.
FTC Act, 15 U.S.C. §41 et seq.; §5(m)(1)(B), 15 U.S.C. §45(m)(1)(B); §19(b), 15 U.S.C. §57b(b)
What FDA wants
FDA asks the firm to notify it in writing within 15 working days of receipt of the specific steps taken to address the violations, including an explanation, documentation, and any reason for delay. The letter also asks the firm to notify FTC’s Richard Cleland within 15 working days of actions taken to address FTC’s concerns.
Who should pay attention
- dietary supplement brands making fertility or women’s health claims
- online marketers of unapproved drugs
- companies making disease-treatment advertising claims without scientific substantiation
This is a summary. Read the original letter on fda.gov.